• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.

作者信息

Wong Christina, Poblete-Lopez Christine, Vidimos Allison

机构信息

Department of Dermatology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio.

出版信息

J Am Acad Dermatol. 2020 Jun;82(6):1539-1542. doi: 10.1016/j.jaad.2020.02.050. Epub 2020 Feb 21.

DOI:10.1016/j.jaad.2020.02.050
PMID:32092372
Abstract
摘要

相似文献

1
Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.维莫德吉每日给药与周一至周五给药治疗局部晚期基底细胞癌和基底细胞痣综合征的比较：一项回顾性病例系列研究。
J Am Acad Dermatol. 2020 Jun;82(6):1539-1542. doi: 10.1016/j.jaad.2020.02.050. Epub 2020 Feb 21.
2
Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.刺猬通路抑制用于局部晚期眼周基底细胞癌和基底细胞痣综合征
Am J Ophthalmol. 2015 Aug;160(2):220-227.e2. doi: 10.1016/j.ajo.2015.04.040. Epub 2015 Apr 30.
3
Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.基底细胞痣综合征的间歇性维莫德吉治疗
JAMA Dermatol. 2016 Feb;152(2):223-4. doi: 10.1001/jamadermatol.2015.3210.
4
Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.维莫德吉延长隔日给药治疗基底细胞癌的疗效
Dermatol Surg. 2020 Aug;46(8):1109-1112. doi: 10.1097/DSS.0000000000001985.
5
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.维莫德吉治疗晚期基底细胞癌患者：国际开放标签试验STEVIE的初步分析
Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.
6
Reply to: "Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: A retrospective case series".回复：“维莫德吉每日给药与周一至周五给药治疗局部晚期基底细胞癌（laBCC）和基底细胞痣综合征的比较：一项回顾性病例系列研究”
J Am Acad Dermatol. 2020 Sep;83(3):e201-e202. doi: 10.1016/j.jaad.2020.03.124. Epub 2020 May 4.
7
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.维莫德吉在晚期基底细胞癌中的疗效：基于模型的评估，8周剂量中断后疗效得以维持
J Invest Dermatol. 2021 Apr;141(4):930-933. doi: 10.1016/j.jid.2020.07.036. Epub 2020 Sep 22.
8
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.两种间断维莫德吉给药方案治疗多发性基底细胞癌患者（MIKIE）：一项随机、方案对照、双盲、2 期试验。
Lancet Oncol. 2017 Mar;18(3):404-412. doi: 10.1016/S1470-2045(17)30072-4. Epub 2017 Feb 8.
9
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.在一项开放性、前瞻性病例系列临床试验中，评估了短疗程（12-24 周）口服维莫德吉在各种组织学亚型（浸润性、结节性和浅表性）高危或局部晚期基底细胞癌中的疗效、肿瘤缓解率和安全性。
J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10.
10
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.使用维莫德吉治疗基底细胞痣综合征患者的角化囊性牙源性肿瘤以使其缩小。
JAMA Dermatol. 2014 May;150(5):542-5. doi: 10.1001/jamadermatol.2013.7444.

引用本文的文献

1
Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database.与维莫德吉相关的不良事件：一项使用FAERS数据库的真实世界药物警戒研究的见解
Front Pharmacol. 2025 May 16;16:1497708. doi: 10.3389/fphar.2025.1497708. eCollection 2025.
2
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.评估 Hedgehog 通路抑制剂治疗晚期基底细胞癌的耐受性：治疗策略的叙述性综述。
Am J Clin Dermatol. 2024 Sep;25(5):779-794. doi: 10.1007/s40257-024-00870-3. Epub 2024 Jun 19.
3
A Non-Interventional Study on Vismodegib for Basal Cell Carcinoma in Swedish Patients.
维莫德吉治疗瑞典基底细胞癌患者的非干预性研究
Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a211.
4
Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.晚期基底细胞癌的长期管理：当前挑战与未来展望
Cancers (Basel). 2022 Sep 20;14(19):4547. doi: 10.3390/cancers14194547.